Opposing functions of psoriasin (S100A7) and koebnerisin (S100A15) in epithelial carcinogenesis

Current Opinion in Pharmacology

Volumn 13, Issue 4, 2013, Pages 588-594

  Hattinger, Eva ^a   Zwicker, Stephanie ^a   Ruzicka, Thomas ^a   Yuspa, Stuart H ^b   Wolf, Ronald ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KOEBNERISIN; PROTEIN S 100; PSORIASIN; UNCLASSIFIED DRUG;

ARTICLE; BIODEGRADATION; BREAST CANCER; CARCINOGENESIS; CARCINOMA; CELL MIGRATION; CELLULAR DISTRIBUTION; GENE DUPLICATION; GENE EXPRESSION; GENE LOCATION; HEAD AND NECK CANCER; HUMAN; INFLAMMATION; MATRIX DEGRADATION; METASTASIS; NONHUMAN; NUCLEAR REPROGRAMMING; ONCOGENE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; S100 GENE; SEQUENCE HOMOLOGY; SKIN CANCER; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR SEEDING; TUMOR VASCULARIZATION;

EID: 84885956765     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2013.04.007     Document Type: Review

References (70)

1. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57-70. (Pubitemid 30046295)
2. Salama I, Malone PS, Mihaimeed F, Jones JL: A review of the S100 proteins in cancer. Eur J Surg Oncol 2008, 34:357-364. (Pubitemid 351381290)
3. Lukanidin E, Sleeman JP: Building the niche: the role of the S100 proteins in metastatic growth. Semin Cancer Biol 2012, 22:216-225.
4. Gebhardt C, Nemeth J, Angel P, Hess J: S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol 2006, 72:1622-1631. (Pubitemid 44666730)
5. Donato R: Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 2003, 60:540-551.
6. Ruse M, Lambert A, Robinson N, Ryan D, Shon KJ, Eckert RL: S100A7, S100A10, and S100A11 are transglutaminase substrates. Biochemistry 2001, 40:3167-3173. (Pubitemid 32205361)
7. Donato R: Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. Biochim Biophys Acta 1999, 1450:191-231. (Pubitemid 29295473)
8. Donato R: S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 2001, 33:637-668. (Pubitemid 32520962)
9. Marenholz I, Heizmann CW, Fritz G: S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 2004, 322:1111-1122. (Pubitemid 39164640)
10. Tirkkonen M, Tanner M, Karhu R, Kallioniemi A, Isola J, Kallioniemi OP: Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer 1998, 21:177-184. (Pubitemid 28136434)
11. Moinzadeh P, Breuhahn K, Stutzer H, Schirmacher P: Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade - results of an explorative CGH meta-analysis. Br J Cancer 2005, 92:935-941. (Pubitemid 40462642)
12. Madsen P, Rasmussen HH, Leffers H, Honore B, Dejgaard K, Olsen E, Kiil J, Walbum E, Andersen AH, Basse B et al.: Molecular cloning, occurrence, and expression of a novel partially secreted protein 'psoriasin' that is highly up-regulated in psoriatic skin. J Invest Dermatol 1991, 97:701-712.
13. Wolf R, Mirmohammadsadegh A, Walz M, Lysa B, Tartler U, Remus R, Hengge U, Michel G, Ruzicka T: Molecular cloning and characterization of alternatively spliced mRNA isoforms from psoriatic skin encoding a novel member of the S100 family. FASEB J 2003, 17:1969-1971.
14. Buchau AS, Hassan M, Kukova G, Lewerenz V, Kellermann S, Wurthner JU, Wolf R, Walz M, Gallo RL, Ruzicka T: S100A15, an antimicrobial protein of the skin: regulation by E. coli through Toll-like receptor 4. J Invest Dermatol 2007, 127:2596-2604. (Pubitemid 47585068)
15. Glaser R, Harder J, Lange H, Bartels J, Christophers E, Schroder JM: Antimicrobial psoriasin (S100A7) protects human skin from Escherichia coli infection. Nat Immunol 2005, 6:57-64. (Pubitemid 40136696)
16. Hegyi Z, Zwicker S, Bureik D, Peric M, Koglin S, Batycka-Baran A, Prinz JC, Ruzicka T, Schauber J, Wolf R: Vitamin D analog calcipotriol suppresses the Th17 cytokine-induced proinflammatory S100 'alarmins' psoriasin (S100A7) and koebnerisin (S100A15) in psoriasis. J Invest Dermatol 2012, 132:1416-1424.
17. Wolf R, Howard OM, Dong HF, Voscopoulos C, Boeshans K, Winston J, Divi R, Gunsior M, Goldsmith P, Ahvazi B et al.: Chemotactic activity of S100A7 (psoriasin) is mediated by the receptor for advanced glycation end products and potentiates inflammation with highly homologous but functionally distinct S100A15. J Immunol 2008, 181:1499-1506.
18. Wolf R, Voscopoulos CJ, FitzGerald PC, Goldsmith P, Cataisson C, Gunsior M, Walz M, Ruzicka T, Yuspa SH: The mouse S100A15 ortholog parallels genomic organization, structure, gene expression, and protein-processing pattern of the human S100A7/A15 subfamily during epidermal maturation. J Invest Dermatol 2006, 126:1600-1608.
19. Wolf R, Ruzicka T, Yuspa SH: Novel S100A7 (psoriasin)/S100A15 (koebnerisin) subfamily: highly homologous but distinct in regulation and function. Amino Acids 2011, 41:789-796.
20. Celis JE, Rasmussen HH, Vorum H, Madsen P, Honore B, Wolf H, Orntoft TF: Bladder squamous cell carcinomas express psoriasin and externalize it to the urine. J Urol 1996, 155: 2105-2112. (Pubitemid 26146716)
21. Moubayed N, Weichenthal M, Harder J, Wandel E, Sticherling M, Glaser R: Psoriasin (S100A7) is significantly up-regulated in human epithelial skin tumours. J Cancer Res Clin Oncol 2007, 133:253-261.
22. Tripathi SC, Matta A, Kaur J, Grigull J, Chauhan SS, Thakar A, Shukla NK, Duggal R, DattaGupta S, Ralhan R et al.: Nuclear S100A7 is associated with poor prognosis in head and neck cancer. PLoS ONE 2010, 5:e11939.
23. Wolf R, Voscopoulos C, Winston J, Dharamsi A, Goldsmith P, Gunsior M, Vonderhaar BK, Olson M, Watson PH, Yuspa SH: Highly homologous hS100A15 and hS100A7 proteins aredistinctly expressed in normal breast tissue and breast cancer. Cancer Lett 2009, 277:101-107.
24. Zhang H, Zhao Q, Chen Y, Wang Y, Gao S, Mao Y, Li M, Peng A, He D, Xiao X: Selective expression of S100A7 in lung squamous cell carcinomas and large cell carcinomas but not in adenocarcinomas and small cell carcinomas. Thorax 2008, 63:352-359. (Pubitemid 351497949)
25. Chen YC, Hsiao CC, Chen KD, Hung YC, Wu CY, Lie CH, Liu SF, Sung MT, Chen CJ, Wang TY et al.: Peripheral immune cell gene expression changes in advanced non-small cell lung cancer patients treated with first line combination chemotherapy. PLoS ONE 2013, 8:e57053.
26. Paget S: The distribution of secondary growths in cancer of the breast, 1889. Cancer Metastasis Rev 1989, 8:98-101.
27. Broome AM, Ryan D, Eckert RL: S100 protein subcellular localization during epidermal differentiation and psoriasis. J Histochem Cytochem 2003, 51:675-685. (Pubitemid 36520623)
28. Martinsson H, Yhr M, Enerback C: Expression patterns of S100A7 (psoriasin) and S100A9 (calgranulin-B) in keratinocyte differentiation. Exp Dermatol 2005, 14:161-168. (Pubitemid 40394198)
29. Wolf R, Lewerenz V, Buchau AS, Walz M, Ruzicka T: Human S100A15 splice variants are differentially expressed in inflammatory skin diseases and regulated through Th1 cytokines and calcium. Exp Dermatol 2007, 16:685-691. (Pubitemid 47079599)
30. Eckert RL, Lee KC: S100A7 (psoriasin): a story of mice and men. J Invest Dermatol 2006, 126:1442-1444.
31. Leygue E, Snell L, Hiller T, Dotzlaw H, Hole K, Murphy LC, Watson PH: Differential expression of psoriasin messenger RNA between in situ and invasive human breast carcinoma. Cancer Res 1996, 56:4606-4609. (Pubitemid 26338057)
32. Alowami S, Qing G, Emberley E, Snell L, Watson PH: Psoriasin (S100A7) expression is altered during skin tumorigenesis. BMC Dermatol 2003, 3:1.
33. Zhang H, Wang Y, Chen Y, Sun S, Li N, Lv D, Liu C, Huang L, He D, Xiao X: Identification and validation of S100A7 associated with lung squamous cell carcinoma metastasis to brain. Lung Cancer 2007, 57:37-45. (Pubitemid 46843348)
34. Deol YS, Nasser MW, Yu L, Zou X, Ganju RK: Tumor-suppressive effects of psoriasin (S100A7) are mediated through the betacatenin/ T cell factor 4 protein pathway in estrogen receptorpositive breast cancer cells. J Biol Chem 2011, 286:44845-44854.
35. Amundadottir LT, Johnson MD, Merlino G, Smith GH, Dickson RB: Synergistic interaction of transforming growth factor alpha and c-myc in mouse mammary and salivary gland tumorigenesis. Cell Growth Differ 1995, 6:737-748.
36. Chen CH, Shen J, Lee WJ, Chow SN: Overexpression of cyclin D1 and c-Myc gene products in human primary epithelial ovarian cancer. Int J Gynecol Cancer 2005, 15:878-883. (Pubitemid 41783096)
37. Orsulic S, Huber O, Aberle H, Arnold S, Kemler R: E-cadherin binding prevents beta-catenin nuclear localization and betacatenin/ LEF-1-mediated transactivation. J Cell Sci 1999, 112(Pt 8):1237-1245. (Pubitemid 29218912)
38. Emberley ED, Alowami S, Snell L, Murphy LC, Watson PH: S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast. Breast Cancer Res 2004, 6:R308-R315.
39. Emberley ED, Niu Y, Curtis L, Troup S, Mandal SK, Myers JN, Gibson SB, Murphy LC, Watson PH: The S100A7-c-Jun activation domain binding protein 1 pathway enhances prosurvival pathways in breast cancer. Cancer Res 2005, 65:5696-5702. (Pubitemid 40911172)
40. Dan HC, Cooper MJ, Cogswell PC, Duncan JA, Ting JP, Baldwin AS: Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. Genes Dev 2008, 22:1490-1500. (Pubitemid 351793083)
41. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91:231-241. (Pubitemid 27456390)
42. Bae MK, Ahn MY, Jeong JW, Bae MH, Lee YM, Bae SK, Park JW, Kim KR, Kim KW: Jab1 interacts directly with HIF-1alpha and regulates its stability. J Biol Chem 2002, 277:9-12. (Pubitemid 34952021)
43. Chamovitz DA, Segal D: JAB1/CSN5 and the COP9 signalosome. A complex situation. EMBO Rep 2001, 2:96-101.
44. Emberley ED, Niu Y, Leygue E, Tomes L, Gietz RD, Murphy LC, Watson PH: Psoriasin interacts with Jab1 and influences breast cancer progression. Cancer Res 2003, 63:1954-1961. (Pubitemid 36460863)
45. Tomoda K, Kubota Y, Arata Y, Mori S, Maeda M, Tanaka T, Yoshida M, Yoneda-Kato N, Kato JY: The cytoplasmic shuttling and subsequent degradation of p27Kip1 mediated by Jab1/ CSN5 and the COP9 signalosome complex. J Biol Chem 2002, 277:2302-2310. (Pubitemid 34968817)
46. Murray JI, Tonkin ML, Whiting AL, Peng F, Farnell B, Cullen JT, Hof F, Boulanger MJ: Structural characterization of S100A15 reveals a novel zinc coordination site among S100 proteins and altered surface chemistry with functional implications for receptor binding. BMC Struct Biol 2012, 12:16.
47. Gebhardt C, Riehl A, Durchdewald M, Nemeth J, Furstenberger G, Muller-Decker K, Enk A, Arnold B, Bierhaus A, Nawroth PP et al.: RAGE signaling sustains inflammation and promotes tumor development. J Exp Med 2008, 205:275-285. (Pubitemid 351281593)
48. Eiro N, Vizoso FJ: Inflammation and cancer. World J Gastrointest Surg 2012, 4:62-72.
49. Webb M, Emberley ED, Lizardo M, Alowami S, Qing G, Alfia'ar A, Snell-Curtis LJ, Niu Y, Civetta A, Myal Y et al.: Expression analysis of the mouse S100A7/psoriasin gene in skin inflammation and mammary tumorigenesis. BMC Cancer 2005, 5:17.
50. Nasser MW, Qamri Z, Deol YS, Ravi J, Powell CA, Trikha P, Schwendener RA, Bai XF, Shilo K, Zou X et al.: S100A7 enhances mammary tumorigenesis through upregulation of inflammatory pathways. Cancer Res 2012, 72:604-615.
51. Shaulian E, Karin M: AP-1 as a regulator of cell life and death. Nat Cell Biol 2002, 4:E131-E136. (Pubitemid 34521026)
52. Wolf R, Mascia F, Dharamsi A, Howard OM, Cataisson C, Bliskovski V, Winston J, Feigenbaum L, Lichti U, Ruzicka T et al.: Gene from a psoriasis susceptibility locus primes the skin for inflammation. Sci Transl Med 2010, 2:61ra90.
53. Woessner JF Jr: Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991, 5:2145-2154. (Pubitemid 21905847)
54. Cortez DM, Feldman MD, Mummidi S, Valente AJ, Steffensen B, Vincenti M, Barnes JL, Chandrasekar B: IL-17 stimulates MMP-1 expression in primary human cardiac fibroblasts via p38 MAPK- and ERK1/2-dependent C/EBP-beta, NF-kappaB, and AP-1 activation. Am J Physiol Heart Circ Physiol 2007, 293:H3356-H3365. (Pubitemid 350230876)
55. Kim HS, Kim MH, Jeong M, Hwang YS, Lim SH, Shin BA, Ahn BW, Jung YD: EGCG blocks tumor promoter-induced MMP-9 expression via suppression of MAPK and AP-1 activation in human gastric AGS cells. Anticancer Res 2004, 24:747-753. (Pubitemid 38625017)
56. Ye L, Sun PH, Martin TA, Sanders AJ, Mason MD, Jiang WG: Psoriasin (S100A7) is a positive regulator Q2 of survival and invasion of prostate cancer cells. Urol Oncol 2012, [Epub ahead of print], in press.
57. Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359:843-845.
58. McMahon G: VEGF receptor signaling in tumor angiogenesis. Oncologist 2000, 5(suppl. 1):3-10. (Pubitemid 30225450)
59. Shubbar E, Vegfors J, Carlstrom M, Petersson S, Enerback C: Psoriasin (S100A7) increases the expression of ROS and VEGF and acts through RAGE to promote endothelial cell proliferation. Breast Cancer Res Treat 2012, 134:71-80.
60. Sica A, Schioppa T, Mantovani A, Allavena P: Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anticancer therapy. Eur J Cancer 2006, 42:717-727.
61. Karin M: Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436. (Pubitemid 44050137)
62. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
63. Friedl P, Wolf K: Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 2003, 3:362-374. (Pubitemid 37328856)
64. Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow? Lancet 2001, 357:539-545.
65. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN et al.: Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56. (Pubitemid 32225831)
66. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA: A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 1996, 184: 1101-1109. (Pubitemid 26313567)
67. Kataoka K, Ono T, Murata H, Morishita M, Yamamoto KI, Sakaguchi M, Huh NH: S100A7 promotes the migration and invasion of osteosarcoma cells via the receptor for advanced glycation end products. Oncol Lett 2012, 3:1149-1153.
68. Winston J, Wolf R: Psoriasin (S100A7) promotes migration of a squamous carcinoma cell line. J Dermatol Sci 2012, 67: 205-207.
69. Strell C, Entschladen F: Extravasation of leukocytes in comparison to tumor cells. Cell Commun Signal 2008, 6:10.
70. Morgan MR, Jazayeri M, Ramsay AG, Thomas GJ, Boulanger MJ, Hart IR, Marshall JF: Psoriasin (S100A7) associates with integrin beta6 subunit and is required for alphavbeta6- dependent carcinoma cell invasion. Oncogene 2011, 30:1422-1435.